Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

The following table represents Evolent’s Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance.



	For the Years Ended December 31,
	2019		2018
Services Revenue
Transformation services	$	15,203	$	32,916
Platform and operations services
Clinical solutions	458,991		228,464
Administrative solutions	198,618		264,104

Contract with customer, asset and liability

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):



	As of December 31,
	2019		2018
Short-term receivables ⁽¹⁾	$	71,707	$	78,380
Long-term receivables ⁽¹⁾	709		6,550
Short-term contract assets	1,751		2,102
Long-term contract assets	999		961
Short-term deferred revenue	19,828		20,584
Long-term deferred revenue	1,330		1,502

⁽¹⁾ Excludes pharmacy claims receivable and premiums receivable

Changes in contract assets and deferred revenue for the year ended December 31, 2019, are as follows (in thousands):



	For the Year Ended December 31, 2019
Contract assets
Balance as of beginning-of-period	$	3,063
Reclassification to receivables, as the right to consideration becomes unconditional	(2,177		)
Contract assets recognized, net of reclassification to receivables	1,864
Balance as of end-of-period	$	2,750

Deferred revenue
Balance as of beginning-of-period	$	22,086
Reclassification to revenue, as a result of performance obligations satisfied	(17,867		)
Cash received in advance of satisfaction of performance obligations	16,939
Balance as of end-of-period	$	21,158